Loading quotes...
Forecast
The analysts' average price target is €3.37 (-20.33%). The median is €3.37 (-20.33%).
| Buy |
3 |
| Hold |
1 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
23andMe sued: accused of paying cybercriminals and covering up data leak
California's attorney general accuses 23andMe of ignoring warning signs about suspicious login activity, failing to implement adequate security measures and not properly informing the public about a massive data leak. Investigations found that credential stuffing and a flawed relatives feature allowed access to data from around seven million customers; offers containing customer data appeared on the dark web. The suit also alleges that 23andMe secretly paid the attacker to remove damaging information from the internet and cites violations of California privacy laws. » More on heise.de
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2025 | YoY |
|---|---|---|
| Revenue | 21.57m | - |
| Gross profit | 11.48m | - |
| Net profit | -20.22m | - |
| EBITDA | -22.6m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €13.89m |
Number of shares | 25.25m |
52-week high/low | €11.58 - €0.44 |
| Dividends | No |
Beta | 1.20 |
P/E ratio | -0.06 |
PEG ratio | 0.00 |
P/B ratio | -0.59 |
P/S ratio | 0.08 |
Company profile
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
| Name | 23ANDME INC.CL.A DL-,0001 |
| CEO | Joseph Selsavage |
| Headquarters | South San Francisco,
ca USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 23/11/2020 |
| Employees | 560 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ME |